Počet záznamů: 1

Unmasking Differential Effects of Rosiglitazone and Pioglitazone in the Combination Treatment with n-3 Fatty Acids in Mice Fed a High-Fat Diet

  1. 1.
    0367620 - FGU-C 2012 RIV US eng J - Článek v odborném periodiku
    Kůs, Vladimír - Flachs, Pavel - Kuda, Ondřej - Bardová, Kristina - Janovská, Petra - Svobodová, Michaela - Macek Jílková, Zuzana - Rossmeisl, Martin - Wang-Sattler, R. - Yu, Z. - Illig, T. - Kopecký, Jan
    Unmasking Differential Effects of Rosiglitazone and Pioglitazone in the Combination Treatment with n-3 Fatty Acids in Mice Fed a High-Fat Diet.
    PLoS ONE. Roč. 6, č. 11 (2011), e27126 E-ISSN 1932-6203
    Grant CEP: GA MZd(CZ) NS10528
    Grant ostatní: EC(XE) FP7-244995
    Výzkumný záměr: CEZ:AV0Z50110509
    Klíčová slova: obesity * TZD * fish oil
    Kód oboru RIV: FB - Endokrinologie, diabetologie, metabolizmus, výživa
    Impakt faktor: 4.092, rok: 2011

    We investigated whether pioglitazone (as well as rosiglitazone), a TZD-drug, could elicit the additive beneficial effects when combined with n-3 LC-PUFA. Adult male mice were fed a high-fat diet (cHF) for 8 weeks, or randomly assigned to various dietary treatments (i) cHF+F, cHF with n-3 LC-PUFA concentrate replacing 15% of dietary lipids; (ii) cHF+ROSI, cHF with rosiglitazone; (iii) cHF+F+ROSI; (iv) cHF+PIO, cHF with pioglitazone; and (v) cHF+F+PIO, or chow-fed. Plasma concentrations of 163 metabolites, development obesity, glucose homeostasis, plasma lipid levels and gene expression were evaluated. Both TZDs preserved glucose homeostasis and normal plasma lipid levels while inducing adiponectin. The beneficial effects of TZDs were further augmented by the combination treatments. Our results reveal differential effects of rosiglitazone and pioglitazone and support the notion that n-3 LC-PUFA could be used as add-on treatment to TZDs in order to improve diabetic patient’s therapy
    Trvalý link: http://hdl.handle.net/11104/0202222